<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Advisory Committee; Oncologic Drugs Advisory Committee; Renewal</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Advisory Committee; Oncologic Drugs Advisory Committee; Renewal</h1>
    <div class="metadata">Published: 2026-02-05 11:29:08</div>
    <div class="summary">The Food and Drug Administration (FDA) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2024, expiration date.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2022/12/05/2022-26363/advisory-committee-oncologic-drugs-advisory-committee-renewal" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2022/12/05/2022-26363/advisory-committee-oncologic-drugs-advisory-committee-renewal</a></div>
</body>
</html>
